The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.
Including the new award, the company has been awarded approximately $6 million in six consecutive grants from the National Cancer Institute (NCI) to develop the new, pain-free test for detecting cervical disease.
According to Guided Therapeutics, the GT LightTouch technology systematically and rapidly scans the cervix to identify cancer and pre-cancer painlessly and non-invasively, by analyzing the wavelengths of light reflected from cervical tissue.
The technology distinguishes between normal and diseased tissue, by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require a tissue sample or laboratory analysis, and is designed to provide results immediately. The technology is designed as a device employing a single-use disposable patient interface, the company added.
Mark Faupel, president and CEO of Guided Therapeutics, said: "This grant provides significant non-dilutive resources for us to begin manufacturing LightTouch devices and disposables for an international launch, as we simultaneously complete the FDA pre-market approval application process."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index